AI Immune Marker Breakthrough Could Spare Thousands from Unnecessary Chemo

A landmark study published June 23, 2026 in Nature Communications by researchers at RCSI University of Medicine and Health Sciences and University College Dublin (UCD) has identified a new AI-powered method to analyze immune markers that could help doctors determine which breast cancer patients can safely skip chemotherapy . The findings challenge long-held assumptions about the role of immune cells in treatment response.

The Breakthrough: AI-Driven Immune Analysis to Refine Treatment Decisions

The study focused on ER+HER2− breast cancer, the most common subtype accounting for about 70% of all breast cancer diagnoses . Using advanced AI techniques known as spatial proteomics and spatial transcriptomics, the team analyzed the tumor-immune microenvironment — the complex ecosystem of cells surrounding a tumor.

They developed a method to quantify the density of cytotoxic T-cells (CD8+) in the stromal compartment, the supportive tissue surrounding the tumor. This analysis works from standard pathology samples that are already collected as part of routine care .

The key advance: this AI-based immune profiling significantly improved risk stratification beyond current genomic tests like the Oncotype DX Recurrence Score. This is especially important for the large group of patients who receive an intermediate genomic risk score — the "gray zone" where chemotherapy decisions are most uncertain and overtreatment is common .

The Counterintuitive Finding: When More Immune Cells Mean Worse Outcomes

In what the researchers called the most striking result, the study found that higher stromal CD8+ cytotoxic T-cell density was associated with poorer outcomes in patients who received chemotherapy .

This is deeply counterintuitive because in other breast cancer subtypes — such as triple-negative breast cancer (TNBC) and HER2+ breast cancer — high levels of tumor-infiltrating immune cells typically signal a favorable prognosis and better chemotherapy response .

In the randomized trial cohort of intermediate-risk patients treated with chemotherapy, this unexpected association was statistically significant (ΔLR-χ²: 6.79, p = 0.009), and it was independently validated using whole-resection specimens (ΔLR-χ²: 8.90, p = 0.003) .

The finding suggests that in ER+HER2− disease, a highly inflamed stromal microenvironment may actually indicate a tumor ecosystem that is resistant to chemotherapy — possibly driven by co-occurring immune exhaustion, checkpoint receptor expression (CTLA4, TIGIT, CD96), and tissue remodeling pathways that the study also uncovered .

What This Means for Patients

For patients diagnosed with early-stage ER+HER2− breast cancer, the study offers hope of more personalized treatment. Currently, many women with intermediate genomic risk scores receive chemotherapy even though it may offer little benefit — a problem known as overtreatment.

"The method has the potential to improve both the precision and the equity of treatment for most women with early-stage breast cancer, regardless of where they are treated," the researchers emphasized, noting that because the method works from standard tissue samples (FFPE blocks and routine IHC), it could be implemented broadly .

Next Steps Toward Clinical Implementation

The study's authors outlined a clear path forward:

• Validation in a larger trial — The discovery was made using samples from an Irish cohort within the TAILORx trial. The lead researchers stated that "further validation in larger studies will be required" before the approach can enter clinical practice .

• Commercialization and patent protection — RCSI and UCD have jointly filed a patent for the technology and are actively seeking to commercialize it .

• Further development funding — The work is being funded by the ARC Hub for HealthTech, co-funded by the Government of Ireland and the European Union through the ERDF Northern and Western Regional Programme 2021–2027 .

Bottom Line

The RCSI/UCD study proposes stromal CD8+ density as a candidate predictive biomarker to de-escalate chemotherapy for intermediate-risk ER+HER2− patients. But it needs prospective validation in the full TAILORx dataset before routine clinical use .

For now, the study represents a significant step toward more precise, less toxic cancer treatment — harnessing AI to read the body's own immune signals and make smarter decisions about who truly needs chemotherapy.

Nature Communications (2026). Spatial-immune multi-omics refines prognostication in early-stage ER+HER2− breast cancer and identifies a predictive biomarker for adjuvant chemotherapy. https://www.nature.com/articles/s41467-026-73432-2

RCSI Press Release (23 June 2026). RCSI study finds new markers to reduce chemotherapy overtreatment in breast cancer. https://www.rcsi.com/dublin/news-and-events/news/news-article/2026/06/study-finds-new-markers-to-reduce-chemotherapy-overtreatment